The effects of citalopram, SB-334867 and orexin-1, alone or in various combinations, on the anxiogenic-like effects of REM sleep deprivation in male mice

Sleep deprivation may induce anxiety. On the other hand, anxiety disorders elicit main changes in the quality of sleep. Moreover, orexin and citalopram play a role in the modulation of insomnia and mood diseases. Thus, we planned preclinical research to evaluate the effect of combinations of orexin agents and citalopram on anxiety behavior in rapid eye movement (REM) sleep-deprived mice. For drug intracerebroventricular (i.c.v.) infusion, the guide cannula was surgically implanted in the left lateral ventricle of mice. REM sleep deprivation was conducted via water tank apparatus for 24 h. The anxiety behavior of mice was evaluated using the elevated plus maze (EPM). Our results revealed that REM sleep deprivation reduced the percentage of open arm time (%OAT) and the percentage of the open arm entries (%OAE) but not closed arm entries (locomotor activity) in the EPM test, presenting an anxiogenic response (P < 0.05). We found a sub-threshold dose of SB-334867, orexin-1 receptor antagonist, and orexin-1 which did not alter anxiety reaction in the REM sleep-deprived mice (P > 0.05). Intraperitoneal (i.p.) injections of citalopram (5 and 10 mg/kg) increased both %OAT and %OAE (P < 0.001) representing an anxiolytic effect, but not locomotor activity in the REM sleep-deprived mice. Interestingly, co-treatment of citalopram (1, 5 and 10 mg/kg; i.p.) and SB-334867 (0.1 µg/mouse; i.c.v.) potentiated the anxiolytic effect in the REM sleep-deprived mice. On the other hand, co-treatment of different dosages of citalopram along with a sub-threshold dose of orexin-1 did not alter %OAT, %OAE, and locomotor activity in the REM sleep-deprived mice. We found a synergistic anxiolytic effect of citalopram and SB-334867 in the REM sleep-deprived mice. These results suggested an interaction between citalopram and SB-334867 to prevent anxiogenic behavior in the REM sleep-deprived mice.

[1]  C. H. Summers,et al.  Orexin 1 Receptor Antagonism in the Basolateral Amygdala Shifts the Balance From Pro- to Antistress Signaling and Behavior , 2022, Biological Psychiatry.

[2]  B. Berger,et al.  Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects , 2021, European Neuropsychopharmacology.

[3]  Afzal Misrani,et al.  Citalopram and its use in sleep-deprivation-induced depression , 2021 .

[4]  C. H. Summers,et al.  Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity , 2020 .

[5]  L. Aquili,et al.  Dysregulation of the orexinergic system: A potential neuropeptide target in depression , 2020, Neuroscience & Biobehavioral Reviews.

[6]  C. H. Summers,et al.  Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy , 2020, Brain Research.

[7]  M. Zarrindast,et al.  Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: An isobologram analysis , 2020, Brain Research.

[8]  S. Ahmadi,et al.  Anxiety in rats with bile duct ligation is associated with activation of JNK3 mitogen-activated protein kinase in the hippocampus , 2020, Metabolic Brain Disease.

[9]  C. Long,et al.  Citalopram prevents sleep-deprivation-induced reduction in CaMKII-CREB-BDNF signaling in mouse prefrontal cortex , 2019, Brain Research Bulletin.

[10]  Miguel López,et al.  Orexins/Hypocretins: Key Regulators of Energy Homeostasis , 2019, Front. Endocrinol..

[11]  C. Long,et al.  Differential effects of citalopram on sleep-deprivation-induced depressive-like behavior and memory impairments in mice , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  M. Zarrindast,et al.  Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  C. H. Summers,et al.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression , 2018, Neuropharmacology.

[14]  M. Zarrindast,et al.  The role of omega-3 on modulation of cognitive deficiency induced by REM sleep deprivation in rats , 2018, Behavioural Brain Research.

[15]  H. Plamondon,et al.  Inhibition of TrkB at the nucleus accumbens, using ANA-12, regulates basal and stress-induced orexin A expression within the mesolimbic system and affects anxiety, sociability and motivation , 2017, Neuropharmacology.

[16]  A. Bahi.  Environmental enrichment reduces chronic psychosocial stress-induced anxiety and ethanol-related behaviors in mice , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  M. Zarrindast,et al.  Synergistic effect between D-AP5 and muscimol in the nucleus accumbens shell on memory consolidation deficit in adult male Wistar rats: An isobologram analysis , 2017, Neurobiology of Learning and Memory.

[18]  M. Fendt,et al.  Increased anxiety but normal fear and safety learning in orexin-deficient mice , 2017, Behavioural Brain Research.

[19]  M. Zarrindast,et al.  Additive effect of harmane and muscimol for memory consolidation impairment in inhibitory avoidance task , 2016, Neuroscience.

[20]  Steven V. Fox,et al.  Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man , 2016, Scientific Reports.

[21]  David M. Shade,et al.  Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. , 2016, Journal of psychiatric research.

[22]  M. Nollet,et al.  Role of Orexin in the Pathophysiology of Depression: Potential for Pharmacological Intervention , 2013, CNS Drugs.

[23]  Ibrahim Alhaider,et al.  Send Orders of Reprints at Reprints@benthamscience.net Neurobiological Consequences of Sleep Deprivation , 2022 .

[24]  D. Chapman,et al.  Frequent insufficient sleep and anxiety and depressive disorders among U.S. community dwellers in 20 states, 2010. , 2013, Psychiatric services.

[25]  P. Ghaeli,et al.  Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression , 2013, DARU Journal of Pharmaceutical Sciences.

[26]  S. Tufik,et al.  Relationship between sleep deprivation and anxiety--experimental research perspective. , 2012, Einstein.

[27]  R. Roberts,et al.  Restricted Sleep Among Adolescents: Prevalence, Incidence, Persistence, and Associated Factors , 2011, Behavioral sleep medicine.

[28]  J. Blendy,et al.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression. , 2010, The international journal of neuropsychopharmacology.

[29]  Matthew F. Covington,et al.  Two-Week Treatment With the Selective Serotonin Reuptake Inhibitor Citalopram Reduces Contextual Anxiety but Not Cued Fear in Healthy Volunteers: A Fear-Potentiated Startle Study , 2009, Neuropsychopharmacology.

[30]  L. Thompson,et al.  The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. , 2006, Schizophrenia bulletin.

[31]  C. Grillon,et al.  A Single Dose of the Selective Serotonin Reuptake Inhibitor Citalopram Exacerbates Anxiety in Humans: A Fear-Potentiated Startle Study , 2007, Neuropsychopharmacology.

[32]  André Charles,et al.  Effects of sleep deprivation on Color-Word, Emotional, and Specific Stroop interference and on self-reported anxiety , 2006, Brain and Cognition.

[33]  Mark D. Miller,et al.  Generalized anxiety disorder in late life: lifetime course and comorbidity with major depressive disorder. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[34]  L. Staner.  Sleep and anxiety disorders , 2003, Dialogues in clinical neuroscience.

[35]  Y. Michotte,et al.  Serotonin Reuptake Inhibition by Citalopram in Rat Strains Differing for Their Emotionality , 2000, Neuropsychopharmacology.

[36]  V. Matto,et al.  Acute and Chronic Citalopram Treatment Differently Modulates Rat Exploratory Behavior in the Exploration Box Test: No Evidence for Increased Anxiety or Changes in the [3H]Raclopride Binding , 1999, Pharmacology.

[37]  Á. N. Chonchubhair.  Selective serotonin reuptake inhibitors. , 1998, Anaesthesia.

[38]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[39]  S. File,et al.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat , 1986, Pharmacology Biochemistry and Behavior.